Patent intelligence · US
US 9193740
Bismacrocyclic compounds as hepatitis C virus inhibitors
Bismacrocyclic compounds as hepatitis C virus inhibitors
Patent details — US 9193740
- Jurisdiction
- US
- Status
- granted
- Grant date
- Nov 24, 2015
- Expiration
- Nov 19, 2035
- Applicant
- Enanta Pharmaceuticals, Inc.
- Claims
- 18
- CPC classes
- A61K, A61K31/495, A61K45/06, A61P
Quick answer
US 9193740 (Bismacrocyclic compounds as hepatitis C virus inhibitors) is held by Enanta Pharmaceuticals, Inc.. Status: granted. Granted Nov 24, 2015. Expires Nov 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Enanta Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 18
- CPC classes
- A61K, A61K31/495, A61K45/06, A61P, A61P31/12, A61P31/14
More from Enanta Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12384753
17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
granted -
US 12358921
Antiviral heterocyclic compounds
granted -
US 12297209
Benzodiazepine derivatives as RSV inhibitors
granted -
US 12281140
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
granted -
US 12268694
Combination pharmaceutical agents as RSV inhibitors
granted -
US 12264159
Functionalized heterocycles as antiviral agents
granted -
US 12162857
Antiviral compounds
granted -
US 12145941
Heterocyclic antiviral agents
granted
Frequently asked questions
What is US patent 9193740?
US 9193740 (Bismacrocyclic compounds as hepatitis C virus inhibitors) is held by Enanta Pharmaceuticals, Inc.. Status: granted. Granted Nov 24, 2015. Expires Nov 19, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9193740?
Enanta Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 218 pharmaceutical patents for this assignee.
When does US 9193740 expire?
Our index shows an expiration date of Nov 19, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.